Table 1.
Summary statistics on DNA Damage Response pathway alterations in clinically localized prostate cancer
| Parameters | Normal (unaffected) | Mutated (affected) | p-value |
|---|---|---|---|
| Total sample size, N | 319 | 136 | |
| Age (years), median (range) | 61 (41–77) | 62 (43–78) | 0.034 |
| PSA pre-operative, median (ng/ml), (range), n | 6.8 (2.2–56.4), 125 | 9.7 (2.2–87.0), 39 | Not significant |
| Stage, pathologic American Joint Committee on Cancer Tumor Stage Code, N (%) | Not significant | ||
| pT2 | 127 (39.8) | 47 (34.6) | |
| pT3 | 186 (58.3) | 86 (63.2) | |
| pT4 | 6 (1.9) | 3 (2.2) | |
| Gleason score, pathologic, N (%) | Not significant | ||
| 6 | 28 (8.8) | 9 (6.6) | |
| 7 | 163 (51.1) | 67 (49.3) | |
| 8–10 | 128 (40.1) | 60 (44.1) |